Literature DB >> 35121867

Immunoradiotherapy goes club(bing).

Ralph R Weichselbaum1,2, Sean P Pitroda3,4.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 35121867     DOI: 10.1038/s43018-021-00256-y

Source DB:  PubMed          Journal:  Nat Cancer        ISSN: 2662-1347


× No keyword cloud information.
  10 in total

Review 1.  Radiotherapy and immunotherapy: a beneficial liaison?

Authors:  Ralph R Weichselbaum; Hua Liang; Liufu Deng; Yang-Xin Fu
Journal:  Nat Rev Clin Oncol       Date:  2017-01-17       Impact factor: 66.675

2.  Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.

Authors:  Nasser K Altorki; Timothy E McGraw; Alain C Borczuk; Ashish Saxena; Jeffrey L Port; Brendon M Stiles; Benjamin E Lee; Nicholas J Sanfilippo; Ronald J Scheff; Bradley B Pua; James F Gruden; Paul J Christos; Cathy Spinelli; Joyce Gakuria; Manik Uppal; Bhavneet Binder; Olivier Elemento; Karla V Ballman; Silvia C Formenti
Journal:  Lancet Oncol       Date:  2021-05-18       Impact factor: 41.316

3.  Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

Authors:  Jason J Luke; Jeffrey M Lemons; Theodore G Karrison; Sean P Pitroda; James M Melotek; Yuanyuan Zha; Hania A Al-Hallaq; Ainhoa Arina; Nikolai N Khodarev; Linda Janisch; Paul Chang; Jyoti D Patel; Gini F Fleming; John Moroney; Manish R Sharma; Julia R White; Mark J Ratain; Thomas F Gajewski; Ralph R Weichselbaum; Steven J Chmura
Journal:  J Clin Oncol       Date:  2018-02-13       Impact factor: 44.544

4.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

Authors:  Jeffrey D Bradley; Rebecca Paulus; Ritsuko Komaki; Gregory Masters; George Blumenschein; Steven Schild; Jeffrey Bogart; Chen Hu; Kenneth Forster; Anthony Magliocco; Vivek Kavadi; Yolanda I Garces; Samir Narayan; Puneeth Iyengar; Cliff Robinson; Raymond B Wynn; Christopher Koprowski; Joanne Meng; Jonathan Beitler; Rakesh Gaur; Walter Curran; Hak Choy
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

5.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Corinne Faivre-Finn; Martin Reck; Johan Vansteenkiste; David R Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

Review 6.  Radiotherapy and Immunotherapy for Cancer: From "Systemic" to "Multisite".

Authors:  Ainhoa Arina; Stanley I Gutiontov; Ralph R Weichselbaum
Journal:  Clin Cancer Res       Date:  2020-02-11       Impact factor: 12.531

Review 7.  Clara cell: progenitor for the bronchiolar epithelium.

Authors:  Susan D Reynolds; Alvin M Malkinson
Journal:  Int J Biochem Cell Biol       Date:  2009-09-09       Impact factor: 5.085

8.  Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

Authors:  Ronan J Kelly; Jaffer A Ajani; Jaroslaw Kuzdzal; Thomas Zander; Eric Van Cutsem; Guillaume Piessen; Guillermo Mendez; Josephine Feliciano; Satoru Motoyama; Astrid Lièvre; Hope Uronis; Elena Elimova; Cecile Grootscholten; Karen Geboes; Syed Zafar; Stephanie Snow; Andrew H Ko; Kynan Feeney; Michael Schenker; Piotr Kocon; Jenny Zhang; Lili Zhu; Ming Lei; Prianka Singh; Kaoru Kondo; James M Cleary; Markus Moehler
Journal:  N Engl J Med       Date:  2021-04-01       Impact factor: 91.245

9.  DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.

Authors:  Claire Vanpouille-Box; Amandine Alard; Molykutty J Aryankalayil; Yasmeen Sarfraz; Julie M Diamond; Robert J Schneider; Giorgio Inghirami; C Norman Coleman; Silvia C Formenti; Sandra Demaria
Journal:  Nat Commun       Date:  2017-06-09       Impact factor: 14.919

10.  Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Authors:  Nancy Y Lee; Robert L Ferris; Amanda Psyrri; Robert I Haddad; Makoto Tahara; Jean Bourhis; Kevin Harrington; Peter Mu-Hsin Chang; Jin-Ching Lin; Mohammad Abdul Razaq; Maria Margarida Teixeira; József Lövey; Jerome Chamois; Antonio Rueda; Chaosu Hu; Lara A Dunn; Mikhail Vladimirovich Dvorkin; Steven De Beukelaer; Dmitri Pavlov; Holger Thurm; Ezra Cohen
Journal:  Lancet Oncol       Date:  2021-04       Impact factor: 54.433

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.